{"id":28539,"date":"2023-04-24T07:00:00","date_gmt":"2023-04-24T07:00:00","guid":{"rendered":"https:\/\/www.ipsen.com\/statement\/ipsen-annonce-sa-decision-darreter-definitivement-la-distribution-des-cartouches-nutropinaq-somatropine\/"},"modified":"2024-07-29T06:59:27","modified_gmt":"2024-07-29T04:59:27","slug":"ipsen-announces-decision-to-permanently-discontinue-distribution-of-nutropinaq-somatropin-cartridges","status":"publish","type":"statements","link":"https:\/\/www.ipsen.com\/fr\/declaration\/ipsen-announces-decision-to-permanently-discontinue-distribution-of-nutropinaq-somatropin-cartridges\/","title":{"rendered":"Ipsen annonce sa d\u00e9cision d’arr\u00eater d\u00e9finitivement la distribution des cartouches NutropinAq\u00ae (somatropine)"},"content":{"rendered":"\n

Ipsen annonce sa d\u00e9cision d’arr\u00eater d\u00e9finitivement la distribution des cartouches NutropinAq\u00ae (somatropine)<\/strong><\/p>\n\n\n\n

Ipsen s’engage \u00e0 apporter des m\u00e9dicaments innovants \u00e0 la communaut\u00e9 des maladies rares o\u00f9 il existe un besoin m\u00e9dical significatif non satisfait et un manque d’innovation dans les traitements.<\/p>\n\n\n\n

Pour poursuivre cet engagement, il est n\u00e9cessaire d’entreprendre une r\u00e9vision r\u00e9guli\u00e8re de notre portefeuille de m\u00e9dicaments, afin de s’assurer qu’Ipsen r\u00e9ponde aux besoins de la communaut\u00e9, en fournissant des options de traitement aux professionnels de sant\u00e9 l\u00e0 o\u00f9 il n’en existe pas ou peu, et en s’assurant que les meilleures solutions possibles sont disponibles pour les patients afin de g\u00e9rer leurs conditions.<\/p>\n\n\n\n

Apr\u00e8s avoir soigneusement \u00e9tudi\u00e9 l’impact de toute action sur les prescripteurs et les utilisateurs de nos m\u00e9dicaments, Ipsen a pris la d\u00e9cision d’arr\u00eater d\u00e9finitivement la distribution des cartouches de NutropinAq\u00ae (somatropine), l’un des nombreux m\u00e9dicaments approuv\u00e9s pour traiter les enfants et les adolescents souffrant d’un retard de croissance d\u00fb \u00e0 un d\u00e9ficit en hormone de croissance (GHD), \u00e0 une insuffisance r\u00e9nale chronique (CRI) ou au syndrome de Turner (TS), ainsi que les patients adultes souffrant de GHD. Cela se fera dans les pays o\u00f9 Ipsen d\u00e9tient l’autorisation de mise sur le march\u00e9, y compris l’Union europ\u00e9enne, le Royaume-Uni et l’Australie, au plus tard en avril 2024.<\/p>\n\n\n\n

Ipsen estime que la d\u00e9cision d’arr\u00eater la distribution des cartouches NutropinAq\u00ae n’aura pas d’impact n\u00e9gatif sur la continuit\u00e9 ou la qualit\u00e9 des soins des patients p\u00e9diatriques vivant avec un retard de croissance d\u00fb au GHD, \u00e0 l’IRC ou au TS, ou des patients adultes atteints de GHD. NutropinAq\u00ae est commercialis\u00e9 depuis de nombreuses ann\u00e9es et a \u00e9t\u00e9 mis \u00e0 disposition \u00e0 une \u00e9poque o\u00f9 il existait peu d’autres options th\u00e9rapeutiques. Au fil des ans, nous avons constat\u00e9 une augmentation de l’innovation dans ce domaine th\u00e9rapeutique, avec l’approbation et la mise \u00e0 disposition de nombreux traitements efficaces. Dans ce contexte, nous estimons que NutropinAq\u00ae n’a plus de raison d’\u00eatre.<\/p>\n\n\n\n

Ipsen prend contact avec les m\u00e9decins qui prennent en charge les patients susceptibles d’\u00eatre affect\u00e9s, afin de s’assurer qu’ils soient pleinement inform\u00e9s et de leur laisser suffisamment de temps pour discuter des options de traitement alternatives et convenir d’une approche pour la poursuite de leurs soins. Nous communiquons \u00e9galement avec d’autres organisations cl\u00e9s et les autorit\u00e9s comp\u00e9tentes, afin de nous assurer que nous menons ce processus de mani\u00e8re professionnelle et positive, en minimisant toute perturbation.<\/p>\n\n\n\n

Nous restons pleinement engag\u00e9s \u00e0 soutenir les personnes qui vivent avec une maladie rare. Apr\u00e8s des ann\u00e9es de collaboration avec la communaut\u00e9 des maladies rares dans le cadre de NutropinAq\u00ae, nous savons que nous pouvons tirer parti de notre grande exp\u00e9rience dans ce domaine dans les ann\u00e9es \u00e0 venir pour continuer \u00e0 d\u00e9velopper et \u00e0 fournir des solutions qui r\u00e9pondent aux importants besoins non satisfaits qui existent malheureusement encore dans le domaine des maladies rares.<\/p>\n\n\n\n

Pour de plus amples informations, veuillez contacter<\/strong>
Anna Gibbins
Global Head Franchise Communications, Rare Diseases
anna.gibbins@ipsen.com<\/u><\/a><\/p>\n\n\n\n

\"\"\/<\/figure>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":3,"template":"","categories":[3542,3551],"tags":[],"class_list":["post-28539","statements","type-statements","status-publish","has-post-thumbnail","hentry","category-mediastatement-fr","category-rare-diseases-mediastatement-fr","entry"],"acf":[],"yoast_head":"\nArr\u00eat d\u00e9finitif de la distribution des cartouches NutropinAq (somatropine) | D\u00e9claration Ipsen<\/title>\n<meta name=\"description\" content=\"Lisez la d\u00e9claration officielle d\u2019Ipsen sur sa d\u00e9cision d\u2019arr\u00eater d\u00e9finitivement la distribution des cartouches NutropinAq (somatropine).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/declaration\/ipsen-announces-decision-to-permanently-discontinue-distribution-of-nutropinaq-somatropin-cartridges\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arr\u00eat d\u00e9finitif de la distribution des cartouches NutropinAq (somatropine) | D\u00e9claration Ipsen\" \/>\n<meta property=\"og:description\" content=\"Lisez la d\u00e9claration officielle d\u2019Ipsen sur sa d\u00e9cision d\u2019arr\u00eater d\u00e9finitivement la distribution des cartouches NutropinAq (somatropine).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/declaration\/ipsen-announces-decision-to-permanently-discontinue-distribution-of-nutropinaq-somatropin-cartridges\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-29T04:59:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/04\/Media-Statement_FR.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"440\" \/>\n\t<meta property=\"og:image:height\" content=\"440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/declaration\/ipsen-announces-decision-to-permanently-discontinue-distribution-of-nutropinaq-somatropin-cartridges\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/declaration\/ipsen-announces-decision-to-permanently-discontinue-distribution-of-nutropinaq-somatropin-cartridges\/\",\"name\":\"Arr\u00eat d\u00e9finitif de la distribution des cartouches NutropinAq (somatropine) | D\u00e9claration Ipsen\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/declaration\/ipsen-announces-decision-to-permanently-discontinue-distribution-of-nutropinaq-somatropin-cartridges\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/declaration\/ipsen-announces-decision-to-permanently-discontinue-distribution-of-nutropinaq-somatropin-cartridges\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/04\/Media-Statement_FR.jpg\",\"datePublished\":\"2023-04-24T07:00:00+00:00\",\"dateModified\":\"2024-07-29T04:59:27+00:00\",\"description\":\"Lisez la d\u00e9claration officielle d\u2019Ipsen sur sa d\u00e9cision d\u2019arr\u00eater d\u00e9finitivement la distribution des cartouches NutropinAq (somatropine).\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/declaration\/ipsen-announces-decision-to-permanently-discontinue-distribution-of-nutropinaq-somatropin-cartridges\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/declaration\/ipsen-announces-decision-to-permanently-discontinue-distribution-of-nutropinaq-somatropin-cartridges\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/declaration\/ipsen-announces-decision-to-permanently-discontinue-distribution-of-nutropinaq-somatropin-cartridges\/#primaryimage\",\"url\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/04\/Media-Statement_FR.jpg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/04\/Media-Statement_FR.jpg\",\"width\":440,\"height\":440},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/declaration\/ipsen-announces-decision-to-permanently-discontinue-distribution-of-nutropinaq-somatropin-cartridges\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen annonce sa d\u00e9cision d’arr\u00eater d\u00e9finitivement la distribution des cartouches NutropinAq\u00ae (somatropine)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arr\u00eat d\u00e9finitif de la distribution des cartouches NutropinAq (somatropine) | D\u00e9claration Ipsen","description":"Lisez la d\u00e9claration officielle d\u2019Ipsen sur sa d\u00e9cision d\u2019arr\u00eater d\u00e9finitivement la distribution des cartouches NutropinAq (somatropine).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/declaration\/ipsen-announces-decision-to-permanently-discontinue-distribution-of-nutropinaq-somatropin-cartridges\/","og_locale":"fr_FR","og_type":"article","og_title":"Arr\u00eat d\u00e9finitif de la distribution des cartouches NutropinAq (somatropine) | D\u00e9claration Ipsen","og_description":"Lisez la d\u00e9claration officielle d\u2019Ipsen sur sa d\u00e9cision d\u2019arr\u00eater d\u00e9finitivement la distribution des cartouches NutropinAq (somatropine).","og_url":"https:\/\/www.ipsen.com\/fr\/declaration\/ipsen-announces-decision-to-permanently-discontinue-distribution-of-nutropinaq-somatropin-cartridges\/","og_site_name":"Global","article_modified_time":"2024-07-29T04:59:27+00:00","og_image":[{"width":440,"height":440,"url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/04\/Media-Statement_FR.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/declaration\/ipsen-announces-decision-to-permanently-discontinue-distribution-of-nutropinaq-somatropin-cartridges\/","url":"https:\/\/www.ipsen.com\/fr\/declaration\/ipsen-announces-decision-to-permanently-discontinue-distribution-of-nutropinaq-somatropin-cartridges\/","name":"Arr\u00eat d\u00e9finitif de la distribution des cartouches NutropinAq (somatropine) | D\u00e9claration Ipsen","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/declaration\/ipsen-announces-decision-to-permanently-discontinue-distribution-of-nutropinaq-somatropin-cartridges\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/declaration\/ipsen-announces-decision-to-permanently-discontinue-distribution-of-nutropinaq-somatropin-cartridges\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/04\/Media-Statement_FR.jpg","datePublished":"2023-04-24T07:00:00+00:00","dateModified":"2024-07-29T04:59:27+00:00","description":"Lisez la d\u00e9claration officielle d\u2019Ipsen sur sa d\u00e9cision d\u2019arr\u00eater d\u00e9finitivement la distribution des cartouches NutropinAq (somatropine).","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/declaration\/ipsen-announces-decision-to-permanently-discontinue-distribution-of-nutropinaq-somatropin-cartridges\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/declaration\/ipsen-announces-decision-to-permanently-discontinue-distribution-of-nutropinaq-somatropin-cartridges\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/declaration\/ipsen-announces-decision-to-permanently-discontinue-distribution-of-nutropinaq-somatropin-cartridges\/#primaryimage","url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/04\/Media-Statement_FR.jpg","contentUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/04\/Media-Statement_FR.jpg","width":440,"height":440},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/declaration\/ipsen-announces-decision-to-permanently-discontinue-distribution-of-nutropinaq-somatropin-cartridges\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Ipsen annonce sa d\u00e9cision d’arr\u00eater d\u00e9finitivement la distribution des cartouches NutropinAq\u00ae (somatropine)"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]}]}},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/statements\/28539","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/statements"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/statements"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"version-history":[{"count":1,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/statements\/28539\/revisions"}],"predecessor-version":[{"id":32695,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/statements\/28539\/revisions\/32695"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media\/26626"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=28539"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=28539"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=28539"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}